| Literature DB >> 25242241 |
Almudena Pérez-Rodríguez1, Esther Lourés1, Ángela Rodríguez-Trillo1, Joana Costa-Pinto1, Aránzazu García-Rivero2, Ana Batlle-López3, Javier Batlle4, María Fernanda López-Fernández1.
Abstract
Congenital thrombotic thrombocytopenic purpura (TTP), also known as Upshaw-Schulman syndrome, is associated with an inherited deficiency of ADAMTS13, a von Willebrand factor-cleaving protease. It is a rare, life-threatening disorder characterized by thrombocytopenia, hemolytic anemia, neurological symptoms, renal dysfunction, and fever resulting from formation of platelet thrombi within the microvasculature. Patients have initial episodes mainly during infancy or early childhood, and are conventionally treated with fresh frozen plasma. However, a more appropriate approach based on recombinant ADAMTS13 is slated to begin shortly. Mutations throughout the ADAMTS13 have been identified in congenital TTP patients. The prevalence of this entity is probably underestimated because it is often not suspected, the clinical course is usually heterogeneous and most of the symptoms are common to other diseases. The present review summarizes our current knowledge about Upshaw-Schulman syndrome.Entities:
Keywords: ADAMTS13; Mutation; Thrombotic thrombocytopenic purpura; Upshaw-Schulman syndrome
Mesh:
Substances:
Year: 2014 PMID: 25242241 DOI: 10.1016/j.thromres.2014.09.004
Source DB: PubMed Journal: Thromb Res ISSN: 0049-3848 Impact factor: 3.944